N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility

  title={N-acetylcysteine for antioxidant therapy: pharmacology and clinical utility},
  author={S. Dodd and O. Dean and D. Copolov and G. Malhi and M. Berk},
  journal={Expert Opinion on Biological Therapy},
  pages={1955 - 1962}
  • S. Dodd, O. Dean, +2 authors M. Berk
  • Published 2008
  • Medicine
  • Expert Opinion on Biological Therapy
  • Background: Glutathione is an endogenous antioxidant and has a ubiquitous role in many of the body's defences. Treatment with N-acetylcysteine (NAC) has been shown to increase levels of glutathione. NAC has been proposed as a treatment for several illnesses. Objectives: The efficacy and tolerability of NAC was examined across a range of conditions to evaluate the evidence supporting the use of NAC for each indication. Methods: A literature search was conducted using PubMed. Information was also… CONTINUE READING
    210 Citations
    N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.
    • 352
    • PDF
    N-Acetylcysteine amide: a derivative to fulfill the promises of N-Acetylcysteine
    • 60
    The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial.
    • 136
    The promise of N-acetylcysteine in neuropsychiatry.
    • 297
    • PDF
    The chemistry and biological activities of N-acetylcysteine.
    • 431
    • PDF
    N-acetylcysteine in addiction management: current knowledge and future perspectives
    • PDF


    N-Acetylcysteine--a safe antidote for cysteine/glutathione deficiency.
    • 499
    • PDF
    N-acetylcysteine -- passe-partout or much ado about nothing?
    • 116
    Clinical Pharmacokinetics of N-Acetylcysteine
    • 274
    Pharmacokinetic and pharmacodynamic studies of N-acetylcysteine, a potential chemopreventive agent during a phase I trial.
    • L. Pendyala, P. Creaven
    • Medicine
    • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
    • 1995
    • 74
    • PDF
    N-Acetyl Cysteine as a Glutathione Precursor for Schizophrenia—A Double-Blind, Randomized, Placebo-Controlled Trial
    • 432
    Effect of intravenous N-acetylcysteine infusion on haemostatic parameters in healthy subjects
    • 39
    • PDF
    N-Acetylcysteine as a Potential Antidote and Biomonitoring Agent of Methylmercury Exposure
    • 51
    • PDF
    High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis.
    • 224
    • PDF
    An open-label trial of N-acetylcysteine for the treatment of cocaine dependence: A pilot study
    • 163